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Identifying ductal carcinoma in situ (DCIS) patients at highest risk for recurrence after breast conserving surgery
(BCS) remains a clinical concern. Subjecting all such patients to radiotherapy may be unnecessary. The Van Nuys
Prognostic Index (VNPI) is a simple scoring system for predicting the risk of local recurrence in patients with DCIS.
We reviewed patients with DCIS applying the VNPI score system. A total of 184 DCIS patients who underwent
surgery at our institution between January 2003 and December 2011 were identified. Patients were not treated
according to VNPI guidelines; rather, radiation therapy was applied at each surgeon’s discretion. All patients with
hormonal receptor positive tumors were treated with hormonal therapy. Pathology reports were reviewed and VNPI
scores of each DCIS calculated. Of the 184 patients, 52 (28.3%), 115 (62.5%) and 17 (9.2%) had low, intermediate and
high VNPI scores, respectively. Six of the 184 patients (3.3%) developed ipsilateral local recurrence, five in the
intermediate and one in the high VNPI score group. Of the five in the intermediate group, three (60%) were in
patients with ER-negative tumors. VNPI score itself was not associated with recurrence (P = 0.145). Factors associated
with recurrence included tumor size (hazard ratio [HR] 6.88), grade (HR 9.07) and hormone receptor status (HR
11.75). Radiotherapy did not significantly improve recurrence rates in patients with low and intermediate risk DCIS,
especially in those with ER-positive tumors. Radiotherapy can be omitted in patients with ER-positive intermediate
score DCIS and in patients with low score DCIS.
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DCIS of the breast encompasses a heterogeneous spectrum
of diseases, characterized by the proliferation of cancer cells
within the ducts without invasion of the surrounding stro-
mal tissue (Harris et al. 1992). Although little is known
regarding the natural history of DCIS, patients with DCIS
have a potential risk of invasive cancer (Robinson et al.
2008); therefore its management is similar to that for early
invasive breast cancer (Masson and Bahl 2013). Studies of
DCIS treated with excision reported 5-year local recurrence
(LR) rates of 6–15% (Ottesen et al. 2000; Schwartz et al.
1992; Baird et al. 1990). Due to the risk of recurrence fol-
lowing breast conserving surgery (BCS), patients with DCIS* Correspondence: hgbreast@gmail.com
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in any medium, provided the original work is pfrequently receive adjuvant radiotherapy (RT). RT following
surgery may reduce the LR rate by about 50%, and a meta-
analysis of four randomized studies comparing wide exci-
sion with and without RT showed that RT significantly
reduced recurrence (odds ratio [OR] 0.40; 95% confidence
interval [CI] 0.33-0.60, p < 0.00001) (Viani et al. 2007).
At the time of those studies, however, pathologic factors
related to local control were largely unknown, resulting in
underestimation of invasiveness and margin status. Al-
though BCS followed by RT has become the standard of
management in DCIS, several retrospective series have
suggested that adjuvant RT may be omitted for patients at
lower risk for recurrence. Identifying patient subgroups
likely to show local control without additional RT is there-
fore important, since RT has various side effects, ranging
from skin reactions to radiation pneumonitis. Pulmonary
toxicities include lung cancer and pulmonary fibrosisOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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affect patient quality of life. Thus, the benefits of RT with
respect to local control must be compared with its risks of
side effects.
Historical data on tumor recurrence have led to the de-
velopment of tools predicting the need for adjuvant treat-
ment, with the Van Nuys Prognostic Index (VNPI) being
the most widely used. The VNPI was developed from a
retrospective analysis of a large database of patients with
DCIS (Silverstein et al. 1996). Factors included in the
VNPI are tumor size, grade, surgical margin and patient
age, resulting in scores ranging from 4 to 12 (Table 1). Pa-
tients at low risk can undergo excision only, those at inter-
mediate risk require adjuvant RT following BCS and those
at high risk require mastectomy. The present study inves-
tigated outcomes in patients with DCIS who underwent
BCS with or without RT at our institution. We also ana-
lyzed the results using the VNPI scoring system.
Patients and methods
A review of our institution’s medical records identified
184 patients with DCIS who underwent surgery between
January 2003 and December 2011. Patients with a prior
history of cancer and those with DCIS with microinvasion
were excluded. Clinicopathologic characteristics evaluated
included patient age, tumor size, grade, margin status, and
tumor biology, and adjuvant therapies were also noted.
Surgical treatment options were BCS or mastectomy, de-
pending on various clinical factors. Although all pathology
reports included VNPI scores, these scores were not
regarded as absolute in selecting treatment. If surgical mar-
gin status was close or positive, re-excision or total mastec-
tomy was performed. No patient underwent RT after
mastectomy. The RT dose to the wholebreast was 50.4 Gy/
28 fx, with tumor bed boost given to all RT patients with
10 Gy/5 fx. Patients with hormone receptor positive tumors
were treated with adjuvant hormonal therapy.
Statistical analysis
Data were statistically analyzed using SPSS version 18
(SPSS Inc, Chicago, IL). Continuous variables were com-
pared using variance analysis and categorical variables
were compared using the chi-square test. Disease free
survival (DFS) was defined as the interval from the dateTable 1 Van Nuys Prognostic index, modified from
Silverstein MJ; DCIS of the breast 2nd ed. 2002
Score 1 2 3
Size (mm) ≤15 16-40 ≥41





Grade 3 with or
without necrosis
Age >60 40-60 <40of surgery to the date of recurrence. DFS was estimated
by the Kaplan-Meier method and compared using the
log-rank test. Cox proportional hazards regression models
were used to assess unadjusted hazard ratios (HRs), with
the latter calculations performed using SAS (SAS Institute,
Cary, NC) software. A p value < 0.05 was defined as statis-
tically significant.
Results
Patient characteristics are shown in Table 2. The mean age
was 49 years, with 12% aged <40 years and 75% aged
41–60 years. Mean tumor size was 24.8 mm, with 76% of
the tumors being of low to intermediate grade and 72.8%
being ER-positive. Of the 184 patients, 127 (69.0%) under-
went BCS and 57 (31.0%) underwent total mastectomy
(TM). In addition, 31 (16.8%) patients underwent no axil-
lary procedure, 109 (59.2%) underwent sentinel lymph
node biopsy only, and 44 (23.9%) underwent axillary
lymph node dissection. Margin widths were determined
after the final excision in the patients who underwent








Table 3 Characteristics of patients with and without
recurrence in breast conserving group
Variable Recurrence (n=6) No recurrence (n=121) P
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ER negative 4(66.7%) 27(22.3%)
PR positive 2(33.3%) 83(68.6%)
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Tamoxifen 2(33.3%) 93(76.9%) .035
Radiation 6(100.0%) 89(73.6%) .336
Kim et al. SpringerPlus 2014, 3:405 Page 3 of 9
http://www.springerplus.com/content/3/1/405margins. Margins >9 mm were attained in 50 patients
(39.4%), final margins 1–9 mm in 59 patients (46.5%), and
final margins <1 mm in 18 patients (14.2%). Most patients
(90.8%) had low to intermediate VNPI scores. Of the 127
patients who underwent BCS, 38 (29.9%) had low risk, 75
(59.1%) had intermediate risk, and 14 (11%) had high risk
VNPI scores (Table 3). Of the 57 patients who underwent
TM, 14 (24.6%) had low risk and 43 (75.4%) had inter-
mediate risk VNPI scores. None of the patients in the TM
group had a high VNPI score, since the margins after TM
were estimated to be ≥10 mm. All patients with high risk
VNPI scores underwent postoperative RT, whereas those
with low and intermediate VNPI scores underwent post-
operative RT at the discretion of the surgeon. All hormone
receptor positive patients were treated with tamoxifen.
Median follow-up period was 66 months. Six of the 184
patients (3.3%) developed ipsilateral local recurrence 33 to
96 months postoperatively (median, 50.5 months). Recur-
rence profiles are shown in Table 4. The 6-year ipsilateral
breast tumor recurrence (IBTR)-free survival rate was
96.7% (Figure 1). Three of the recurrences were invasive
(50%). No patient died during the follow-up period. None
of the patients in the TM group experienced a tumor re-
currence, compared with 6 of 127 in the BCS group. Five
of six recurrences occurred in patients with intermediate
VNPI scores, with the sixth in a patient with a high VNPI
score, the latter 47 months postoperatively. This patient
was a 42 year old woman with an ER negative tumor
47 mm in size of grade 3; the patient had a VNPI score of
10 and received postoperative RT. Statistically significant
differences in tumor size, grade, and ER status were
observed between patients with and without recurrence
(Table 3). Univariate analysis using the Kaplan-Meier log
rank test showed that tumor size (HR 6.88), grade (HR
9.07) and hormone receptor status (HR 11.75) were asso-
ciated with recurrence (Tables 5 and 6). ER status was a
greater predictor of recurrence than tumor size or grade.
Univariate analysis using a Cox regression model showed
that RT was not associated with recurrence (HR = 11.41;
95% CI 0.475-273.931, P =0.1334). Age, margin width,
Her-2 status and Ki-67 were not significantly associated
with DFS. Similarly, when VNPI scores were used to
predict recurrence, there were no statistically significant
differences in recurrence rates among patients with low,
intermediate and high scores (Figure 2). In addition, there
was no relationship between VNPI and prognosis, regard-
less of age (data not shown).
Most recurrences occurred in the intermediate VNPI
score group. Of the 14 patients in this group (18.7%) who
did not undergo RT, none showed evidence of tumor recur-
rence. In contrast, recurrences occurred in patients who
received RT, with 3 of 5 (60%) occurring in patients with
ER-negative tumors. A retrospective data review showed
that tumor size was significant in determining treatment
Table 4 Profile of patients with ipsilateral breast tumor recurrence
No. Age (yr) Surgery Size (mm) Margin width (mm) Pathology VNPI score ER/PR/Her2 RT IBTR type Time to
recurrence (month)
1 51 BCS 42 25 G3 with necrosis 9 +/+/- yes Invasive 96
2 36 BCS 55 3 G2 without necrosis 9 -/-/+ yes Invasive 49
3 45 BCS 50 10 G2 without necrosis 7 +/+/- yes Invasive 52
4 50 BCS 95 10 G3 with necrosis 9 -/-/- yes DCIS 44
5 42 BCS 47 5 G3 with necrosis 10 -/-/+ yes DCIS 56
6 52 BCS 18 10 G3 with necrosis 8 -/-/+ yes DCIS 33
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Surgeons have a tendency to add RT or to perform a mast-
ectomy based on tumor size rather than margin width
(Table 7). However, adding RT did not affect local control
of disease.
Discussion
Attempts to validate the VNPI scoring system have
yielded mixed results (MacAusland et al. 2007; Di
Saverio et al. 2008; Gilleard et al. 2008; Altintas et al.
2011; Lee et al. 2013; Whitfield et al. 2012; Asjoe et al.
2007). Such studies have had uneven population distri-
butions, with most patients having low to intermediate
scores. Although patient age, tumor size, and tumor
grade were set at patient diagnosis, margin width may be
downgraded by re-excision or TM. Such efforts to
salvage treatment have resulted in a disproportionately
low rate of patients with high VNPI scores (MacAusland
et al. 2007; Di Saverio et al. 2008; Whitfield et al. 2012). A
prospective trial with a short follow-up time found that, in
the absence of RT or tamoxifen, downscoring the risk of
recurrence made it impossible to analyze factors normallyFigure 1 Ipsilateral breast tumor recurrence (IBTR)-free survival.because of the small number of recurrences (Wong et al.
2006). In our study, however, the VNPI scoring system
was not a treatment guideline, with patients receiving RT
at the discretion of individual surgeons or patients. The
proportion of patients who underwent TM in the inter-
mediate risk group was relatively high (36.4%), and was
only somewhat lower in the low risk group (26.9%),
which may reflect patient preference, such as for a de-
finitive cure.
About half of the IBTRs were invasive, similar to
findings of approximately 50% invasive relapses after
BCS in other studies (Schwartz et al. 1992; Lagios
1990; Nakamura et al. 2002; de Mascarel et al. 2000).
The proportion of patients deemed at high risk was
11%, higher than in other studies. Most of the recur-
rences occurred in patients with intermediate scores,
with only one occurring in the high risk group.
Of the 17 patients in the high risk group, 14 (82.4%)
underwent BCS followed by RT, whereas only three pa-
tients underwent TM, with recurrences observed in one
(7.1%) and zero patients, respectively. The benefits of RT
could not be determined, however, due to a lack of
Table 5 Clinical prognostic factors in BCS group(n=127),
Kaplan Meier log-rank test
Variable Recurrence No recurrence Percentage P value
(log rank)
Age (yr) .789
≤40 1 17 1/18(5.6%)
41-60 5 91 4/96(4.2%)
≥61 0 13 0
Tumor size (mm) <.001
≤15 0 58 0
16-40 1 42 1/43(2.3%)
≥41 5 21 5/26(19.2%)
Tumor grade .002
1 0 28 0
2 2 67 1/69(1.4%)
3 4 26 4/30(13.3%)
VNPI score .173
4-6 0 38 0
7-9 5 70 5/75(6.7%)
10-12 1 13 1/14(7.1%)
ER status .016
(+) 2 94 2/96(2.1%)
(-) 4 27 4/31(12.9%)
RT .184
Yes 6 89 6/95(6.3%)
No 0 32 0
Table 6 Factors associated with recurrence,univariate
analysis using Cox regression model
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A previous study, which recommended mastectomy in
patients with high risk scores, evaluated VNPI retro-
spectively in only 333 patients, with their findings not
considered evidence-based. This prognostic index can
promote discussions between physicians and patients,
based on tumor parameters obtained after local excision
(Asjoe et al. 2007). Although the benefits of RT are un-
known, the addition of RT to BCS should be compared
clinically with mastectomy plus reconstruction.
We also found that none of the women with BCS who
did not receive RT developed tumor recurrence. In con-
trast, most recurrences were in the intermediate risk
group who received postoperative RT. As in other studies,
we observed no “RT-effect” in our low risk group (Lee
et al. 2013; Whitfield et al. 2012; Asjoe et al. 2007). Con-
trary to previous findings, no “RT-effect” was observed in
our intermediate risk group. RT has been recommended
in all DCIS patients at intermediate risk of recurrence.
However, we found that RT did not decrease recurrence
rate in some intermediate risk patients. That is, following
excision, patients with intermediate risk DCIS could be
safely ‘undertreated’ under some circumstances.Interestingly, 60% of intermediate risk patients with re-
currence had ER-negative DCIS. Of the 127 women in our
study who underwent BCS, with or without RT, 31 (24.4%)
were ER-negative and 96 (75.6%) were ER-positive, with the
former more likely to experience local recurrence than the
latter (9.7% vs 3.7%), or a 7.6% absolute difference. An
evaluation of 132 patients with DCIS treated with BCS
without (n = 33) or with (n = 99) whole-breast RT found an
absolute difference of about 8.5% in rates of local recur-
rence in patients with ER-negative and ER-positive DCIS
(Roka et al. 2004; Provenzano et al. 2003). Indeed, sev-
eral studies have revealed an association between ER-
negative DCIS and risk of recurrence (Ringberg et al.
2001; Provenzano et al. 2003; Kerlikowske et al. 2010).
Several randomized clinical trials may determine the
ability of ER to predict response to endocrine therapy. For
Figure 2 Ipsilateral breast tumor recurrence(IBTR)-free survival. (a) IBTR-free survival according to age (b) IBTR-free survival according to
margin width (c) IBTR-free survival according to VNPI score.
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women and had a median follow-up time of 12 years,
found very small but statistically significant reductions in
rates of breast cancer events among patients randomized
to tamoxifen versus placebo, including a 3.2% reduction in
ipsilateral invasive recurrence, but no change for ipsilateral
DCIS. However, in that study, patients were not selected
to receive tamoxifen on the basis of ER positivity. The de-
gree of benefit may have been higher if only patients with
ER-positive DCIS had been enrolled. Taken together, theseresults suggest that ER is weakly predictive of local recur-
rence following treatment for DCIS (Lari and Kuerer
2011). In the present study, all women with ER-positive
DCIS received tamoxifen, although their adherence was
not evaluated. Of patients who underwent BCS, with or
without RT, 75.6% are ER-positive, suggesting that patients
with DCIS may benefit from endocrine therapy since none
experienced recurrence regardless of RT. The finding that
all recurrences were in patients with ER-negative DCIS in-
dicates that recurrences are due to biologic characteristics
Table 7 Clinicopathologic characteristics in VNPI
intermediate scores according to treatment (TM; total
mastectomy in intermediate VNPI score)
Variable No RTx (n=14) RTx (n=61) TM (n=43) P
Age (yr) 49.1±9.5 48.1±7.9 48.7±9.5 .979
≤40 2(14.3%) 7(11.7%) 6(14.0%)
41-60 11(78.6%) 50(82.0%) 33(76.7%)
≥61 1(7.1%) 4(6.6%) 4(9.3%)
Microcalcification .983
Yes 9(64.3%) 38(62.3%) 28(65.1%)
No 5(35.7%) 23(37.7%) 15(34.9%)
Multifocality .314
Yes 1(7.1%) 9(14.8%) 10(23.3%)
No 13(92.9%) 52(85.2%) 33(76.7%)
Tumor size (mm) 13.93±12.07 29.90±18.11 50.74±23.49 .001
≤15 11(78.6%) 14(23.0%) 1(2.3%)
16-40 2(14.3%) 30(49.2%) 15(34.9%)
≥41 1(7.1%) 17(27.9%) 27(62.8%)
Tumor grade .360
1 2(14.3%) 8(13.1%) 1(2.3%)
2 7(50.0%) 36(59.0%) 28(65.1%)
3 5(35.7%) 17(27.9%) 14(32.6%)
Margin (mm) 8.93±7.97 7.80±7.58 .221
>9 5(35.7%) 18(29.5%) -
1-9 9(64.3%) 32(52.5%) -
<1 0 11(18.0%) -
VNPI score 7.5±0.7 8.2±0.8 8.0±0.9 .021
Receptor status
ER positive 13(92.9%) 40(65.6%) 28(65.1%) .110
PR positive 10(71.4%) 38(62.3%) 21(48.8%) .240
C-erbB2 .636
0 3(21.4%) 6(9.8%) 6(14.0%)
1+ 2(14.3%) 10(16.4%) 11(25.6%)
2+ 3(21.4%) 18(29.5%) 6(14.0%)
3+ 6(42.9%) 26(42.6%) 18(41.9%)
Unknown 0 1(1.7%) 2(4.7%)
Ki67 status (%) 12.8±12.39 13.65±15.54 12.91±15.94 .847
Tamoxifen 12(85.7%) 43(68.9%) 30(69.8%) .467
Recurrence 0 5(8.3%) 0 .418
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ER negativity was significantly also associated with a
higher risk of recurrence than ER positivity (HR = 11.75;
95% CI 0.93-183.74, P value = 0.04) Since only 6 patients
experienced recurrences, our analysis loses considerable
discriminating power, and we were unable to study the
independent contributions of each prognostic factor inmultivariate analysis. Instead, we calculated HR and 95% CI
using a univariate Cox regression model. Our results indi-
cate the relatively greater importance of ER negativity com-
pared to VNPI score. The VNPI score itself did not provide
sufficient evidence to predict prognosis in our cohort.
The question remains whether TM is more beneficial in
high risk patients with ER-negative DCIS. We found that
the ER-negative DCIS rate was 47.1% in the high risk
group, with 37.5% undergoing TM and 62.5% undergoing
BCS with RT. None of the former, and one of the latter,
experienced tumor recurrence, suggesting that mastectomy
has a 1.25-fold higher benefit than BCS with RT. Patients
with large, high grade, ER-negative DCIS may require TM,
whereas those with ER-positive DCIS may be treated with
BCS plus RT.
In the intermediate risk group, the ER-negative DCIS rate
was 30.5%. Of patients in the intermediate risk group,
18.7% did not undergo RT, with almost all of these patients
having ER-positive DCIS. All recurrences were observed in
the RT group, including two (40%) with ER-positive and
three (60%) with ER-negative DCIS. Adherence to tamoxi-
fen treatment was not evaluated, since we assumed good
compliance with hormonal therapy. The benefits of RT
seemed to be greater in patients with ER negative than ER
positive-DCIS, suggesting the importance of a local control
strategy for ER-negative DCIS. In contrast, RT may be un-
necessary in patients with ER-positive intermediate risk
DCIS. Hormonal therapy alone may be sufficient, allowing
patients to avoid the side effects of RT.
We observed no association between margin width and
recurrence. In our study population, only 9.8% had margin
widths <1 mm. The margin widths of most tumors are
large enough after excision; therefore margin status was
not correlated with any other outcomes (Di Saverio et al.
2008; Ringberg et al. 2001; Lim et al. 2014; Yi et al. 2012).
Studies have reported that Ki-67 expression rates and
HER2 and other biological markers are prognostically
significant markers in DCIS patients (Roka et al. 2004;
Ringberg et al. 2001; Provenzano et al. 2003; de Roos
et al. 2007; Menter et al. 2001; Barnes et al. 2005). The
US National Cancer Institute has recently identified a
critical need for investigation and validation of molecu-
lar factors to improve risk stratification of patients with
DCIS, thus facilitating a determination of the optimal
therapy for each individual patient (Allegra et al. 2010).
Although we observed no association between HER2
expression and recurrence, HER2 expression and status
were not evaluated by FISH. Similarly, data on Ki67
expression was not reliably evaluated.
This single institution retrospective analysis had a me-
dian follow-up of 61 months. Longer follow-up is needed
to estimate long-term outcomes. Additionally, selection
bias should be expected due to the heterogeneities of the
study population.
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be omitted in some patients with intermediate risk DCIS.
ER status is important for stratifying risk of recurrence.
RT may be unnecessary in patients with ER-positive inter-
mediate score DCIS. Endocrine treatment should be pro-
vided to all patients with ER-positive DCIS.
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